# Role of oncogenic phosphorylated MED1 in aggressive prostate cancer

> **NIH NIH R01** · DUKE UNIVERSITY · 2020 · $383,629

## Abstract

Project Summary/Abstract
The evolution of prostate cancer from an androgen-dependent state (ADPC) to castration-resistant
adenocarcinoma (CRPC) marks the lethal progression of the disease. Contemporary therapy for CRPC
employs inhibitors of intra-tumoral and adrenal androgen synthesis (e.g. abiraterone acetate) or more potent
androgen receptor (AR) antagonists (e.g. enzalutamide). However, these agents only provide a temporary
response and modest increase in survival indicating a rapid evolution of resistance. In addition to CRPC, a
significant number of patients develop small cell neuroendocrine carcinoma (SCNC) after hormonal therapy.
SCNC is extremely aggressive and rapidly fatal. Importantly, with the widespread use of abiraterone acetate
and enzalutamide, a greater frequency of the SCNC has been observed. Currently, there is no standard
therapy that is effective for SCNC. Thus understanding the pathogenesis of CRPC/SCNC evolution and
development of novel targeted therapies remain urgent needs. In addition, predictive and prognostic
biomarkers that can help “personalize” therapy and improve the precision of clinical trials are necessary. In
preliminary studies, we have found that AKT-induced aberrant phosphorylation of transcription coactivator
Mediator 1 (MED1) is required for UBE2C oncogene expression and for growth of CRPC and/or SCNC cells in
vitro and in vivo. Furthermore, pharmacological AKT inhibition decreases UBE2C oncogene expression and
cell growth in vitro in a phosphorylated MED1 (p-MED1)-specific manner. Importantly, the expression of p-
MED1 significantly increases when human prostate cancer progresses to CRPC and SCNC. These findings
support our hypothesis that AKT-induced aberrant MED1 phosphorylation drives an oncogenic gene
expression program for CRPC/SCNC growth and progression. Our specific aims are to: (1) delineate the
genomic mechanisms of p-MED1 binding to chromatin and global gene regulation in CRPC/SCNC; and (2)
determine the biological impact and clinical relevance of AKT-p-MED1 transcriptional regulation in
CRPC/SCNC. The successful completion of these aims will significantly impact the understanding of the critical
oncogenic role of p-MED1 in CRPC and SCNC, laying the foundation for: (a) developing new therapies
targeting the AKT-p-MED1 transcription axis, (b) employing p-MED1 as a marker for selecting AKT inhibitor-
sensitive patients for “precision medicine” clinical trials, and (c) identifying new predictive and prognostic
biomarkers for CRPC and SCNC.

## Key facts

- **NIH application ID:** 9929554
- **Project number:** 5R01CA200853-05
- **Recipient organization:** DUKE UNIVERSITY
- **Principal Investigator:** STEVEN K CLINTON
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $383,629
- **Award type:** 5
- **Project period:** 2017-07-01 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9929554

## Citation

> US National Institutes of Health, RePORTER application 9929554, Role of oncogenic phosphorylated MED1 in aggressive prostate cancer (5R01CA200853-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9929554. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*